Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next three days.
In the meantime, you can enjoy access to all the latest news, events and resources for different therapy areas on our website.
Assess and address
How can patient perceptions of asthma control affect disease management?
The Salford Lung Study (SLS) was a robust, open-label, pragmatic RCT comparing Relvar with usual care (ICS or ICS/LABA*) in 4233 patients.†1
Proportion of ACT responders at 6 months1
25% more patients
improve their level of asthma control with
Relvar vs 4 other ICS/LABAs in everyday practice1
OR: 1.95, 95% CI: 1.60–2.38
At baseline, the most commonly prescribed ICS/LABAs were: FP/SAL,
BUD/Form and BDP/Form2
*Usual care was ICS or ICS/LABA. ICS monotherapy in the usual care group included beclomethasone, budesonide, ciclesonide and fluticasone. ICS/LABAs in the usual care group included beclomethasone/formoterol, budesonide/formoterol, fluticasone/formoterol and fluticasone/salmeterol.2
This graph has been independently created by GSK from the original data. The same results were first published in Woodcock A, et al. Lancet 2017;390:2247–2255.
Relvar – studied in an RCT in everyday practice1
Proactive asthma control with Relvar improves symptoms vs other ICS/LABAs4
Looking at the individual aspects of the Asthma Control Test (ACT), Relvar treatment provides a higher mean change in symptom improvement from baseline vs other commonly prescribed ICS/LABAs.§4
This graph has been independently created by GSK from the original data. The same results were first published in Svedsater H, et al. Respir Med 2018;141:198–206.
Good symptom control and exacerbations
Good symptom control is strongly associated with reduced risk of exacerbations.5
See what effect Relvar has on exacerbation risk.
Discover Relvar
21st-century molecules[6–9]
Relvar’s unique combination of fluticasone furoate, a potent inhaled corticosteroid, and vilanterol, an ultra-long-β2-agonist, delivers the everyday stability asthma patients need.1,4,6,7,10–16
Footnotes
*Usual care was ICS or ICS/LABA. ICS monotherapy in the usual care group included beclomethasone, budesonide, ciclesonide and fluticasone. ICS/LABAs in the usual care group included beclomethasone/formoterol, budesonide/formoterol, fluticasone/formoterol and fluticasone/salmeterol.2
†Responders were defined as patients who achieved an ACT score of ≥20 or an increase in ACT score from baseline of ≥3 at 24 weeks (primary endpoint). The primary endpoint was met (p<0.0001). Data presented are from a subset of patients prescribed ICS/LABA at baseline who were initiated on Relvar or continued on their ICS/LABA. Data showed a relative difference of 25% and an absolute difference of 14%.1 In this study, there was no difference in serious adverse events reported between Relvar and usual care. The most common serious adverse events of special interest were cardiovascular disease, asthma and bronchospasm, and pneumonia.1
‡Often excluded from traditional RCTs.
§Statistical analysis was not performed on the individual questions of the ACT. Data presented are from a pre-planned analysis from a subset of patients in the ITT population prescribed ICS/LABA at baseline initiated with Relvar or continued on their existing ICS/LABA. Overall mean change in ACT score from baseline was 3.3 for Relvar and 1.8 for ICS/LABAs (p<0.001).4
Abbreviations
ACT, Asthma Control Test; AE, adverse event; BDP, beclomethasone dipropionate; BUD, budesonide; CI, confidence interval; Form, formoterol; FP, fluticasone propionate; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; OR, odds ratio; RCT, randomised controlled trial; SAL, salmeterol; SLS, Salford Lung Study.
Relvar Safety Information17
Contraindications
Hypersensitivity to the active substances or to any of the excipients.
Undesirable effects
Very Common: Headache, Nasopharyngitis.
Common: Infections and infestations, Oropharyngeal pain, Sinusitis, Pharyngitis, Rhinitis, Cough, Dysphonia, Abdominal pain, Arthralgia, Back pain, Fractures, Muscle spasms and Pyrexia.
References
- Woodcock A, et al. Lancet 2017;390:2247–2255.
- GSK Data on File 219213; 2023.
- Herland K, et al. Respir Med 2005;99:11–19.
- Svedsater H, et al. Respir Med 2018;141:198–206.
- GINA. Global strategy for asthma management and prevention, 2023. Available at: www.ginasthma.org. Accessed April 2024.
- Bernstein DI, et al. J Asthma 2015;52:1073–1083.
- Global Datasheet Fluticasone furoate/vilanterol: v13, September 2022.
- Braithwaite I, et al. Respir Med 2016;119:115–121.
- Center for Drug Evaluation and Research. Approval package for Breo Ellipta. Application number: 204275Orig1s000. Accessed April 2024.
- Averell CM, et al. J Asthma 2022;59:1805–1818.
- Daley-Yates P, et al. Adv Ther 2023;40:4042–4059.
- Parimi M, et al. Adv Ther 2020;37:2916–2931.
- van der Palen J, et al. NPJ Prim Care Respir Med 2016;26:16079.
- van der Palen J, et al. Respir Med 2022;205:107031.
- Janson C, et al. Thorax 2020;75:82–84.
- Woodcock A, et al. Thorax 2022;77:1187–1192.
- Relvar Prescribing Information.
GSK does not recommend, endorse, or accept liability for the 3rd party sites.
For more information, please refer to the prescribing information or contact GlaxoSmithKline via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
Gulf.ProductQualityComplaints@gsk.com
Department of Pharmacovigilance & Drug Information |
دائرة التيقظ و المعلومات الدوائية مركز سلامة الدواء وزارة الصحة, سلطنة عمان هاتف: 0096822357687 / 0096822357690 0096822358489 :فاكس pharma-vigil@moh.gov.om :البريد االكتروني https://moh.gov.om/en/ : الموقع االكتروني |
Trademarks are owned by or licensed to the GSK group of companies
PM-RCH-FFV-WCNT-250001 Date of preparation: July 2025
